209 related articles for article (PubMed ID: 16526049)
1. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
2. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
3. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
Bomgaars L; Carberry K; Fraser C; West A; Teruya J
Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
[TBL] [Abstract][Full Text] [Related]
4. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
[TBL] [Abstract][Full Text] [Related]
5. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases.
Poynton AR; Nelson MC; McCance SE; Levine RL; O'Leary PF
Spine (Phila Pa 1976); 2003 Jun; 28(12):E221-3. PubMed ID: 12811284
[TBL] [Abstract][Full Text] [Related]
6. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
7. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
Adams JD; Jones S; Brost BC
J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
[TBL] [Abstract][Full Text] [Related]
8. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors.
de Raucourt E; Barbier C; Sinda P; Dib M; Peltier JY; Ternisien C
Am J Hematol; 2003 Nov; 74(3):187-90. PubMed ID: 14587047
[TBL] [Abstract][Full Text] [Related]
10. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin.
Israels SJ; Israels ED
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):249-54. PubMed ID: 8037345
[TBL] [Abstract][Full Text] [Related]
11. Immune-mediated coagulopathy: a case report.
Naoum JJ
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
[TBL] [Abstract][Full Text] [Related]
12. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
Muntean W; Zenz W; Edlinger G; Beitzke A
Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
[No Abstract] [Full Text] [Related]
13. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin.
Neschis DG; Heyman MR; Cheanvechai V; Benjamin ME; Flinn WR
J Vasc Surg; 2002 Feb; 35(2):400-2. PubMed ID: 11854743
[TBL] [Abstract][Full Text] [Related]
14. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
Tarantino MD; Ross MP; Daniels TM; Nichols WL
J Pediatr Hematol Oncol; 1997; 19(3):226-31. PubMed ID: 9201145
[TBL] [Abstract][Full Text] [Related]
15. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature.
Rodgers GM
J Pediatr Hematol Oncol; 2011 Mar; 33(2):86-8. PubMed ID: 21228719
[TBL] [Abstract][Full Text] [Related]
16. [A case positive for the inhibitor for coagulation factor V].
Nakagoshi R; Takamiya O; Nakata S; Ishikawa S; Higuchi Y; Okumura N; Ogiso Y
Rinsho Byori; 1999 Oct; 47(10):971-5. PubMed ID: 10590673
[TBL] [Abstract][Full Text] [Related]
17. A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population.
Fareed J; Paterson CA; Crean SM
Clin Appl Thromb Hemost; 2011 Apr; 17(2):164-70. PubMed ID: 21078614
[TBL] [Abstract][Full Text] [Related]
18. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
20. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
Streiff MB; Ness PM
Transfusion; 2002 Jan; 42(1):18-26. PubMed ID: 11896308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
